Skip to content

US · OCS · BIOTECHNOLOGY

Oculis Holding AG (OCS) intrinsic value and stock valuation

$7.06as of 2026-11-21 · Mkt cap 690.04M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Oculis Holding AG DCF and intrinsic value

InvestorsCraft values OCS with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from OCS’s statements →

Oculis Holding AG Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Zug, ZG 6300 oculis.com

How the business is doing

Fiscal 2020–2025, USD

Revenue
$0.00
20202025
Net income
-$-94.51M
20202025
Free cash flow
-$-62.51M
20202025
Total equity
$196.3M
20202025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2020–2025, USD
20252024202320222021
Revenue$0.00$690K$0.00$0.00$0.00
Operating income-$-79.15M-$-73.2M-$-80.71M-$-32.38M-$-13.23M
Net income-$-94.51M-$-85.78M-$-88.8M-$-38.7M-$-18.55M
EPSd-$-1.81M-$-2.12M-$-2.97M-$-1.18M-$-566.76K
Operating cash flow-$-62.22M-$-47.5M-$-53.84M-$-25.07M-$-13.82M
Capital expenditure-$-290K-$-230K-$-50K-$-3.55M-$-30K
Free cash flow-$-62.51M-$-47.73M-$-53.89M-$-28.62M-$-13.85M
Total assets$236.2M$120.4M$114.4M$37.1M$58M
Total debt$2.32M$1.18M$600K$123.1M$114.3M
Net debt-$-79.11M-$-26.53M-$-37.72M$103.3M$68M
Total equity$196.3M$73.4M$93.7M-$-97.99M-$-60.95M
Cash and short-term investments$213.3M$98.7M$91.7M$19.8M$46.3M
Income statement
20252024202320222021
Revenue$0.00$690K$0.00$0.00$0.00
Cost of revenue$0.00$52.1M$0.00$0.00$0.00
Gross profit$0.00-$-51.4M$0.00$0.00$0.00
Research and development expenses$54.5M$52.1M$29.3M$22.2M$9.57M
Selling, general and administrative expenses$24.6M$21.8M$14.7M$6.74M$4.1M
Other expenses$0.00-$-52.08M$36.7M$3.41M-$-430K
Operating expenses$79.2M$21.8M$80.7M$32.4M$13.2M
Cost and expenses$79.2M$73.9M$80.7M$32.4M$13.2M
Interest income$1.69M$2.17M$1.59M$130K$20K
Interest expense$800K$640K$1.46M$6.44M$5.12M
Depreciation and amortization$520K$410K$290K$300K$230K
Ebitda-$-93.37M-$-85.53M-$-87.09M-$-31.9M-$-13.17M
Operating income-$-79.15M-$-73.2M-$-80.71M-$-32.38M-$-13.23M
Total other income/expenses, net-$-15.54M-$-12.73M-$-7.98M-$-6.27M-$-5.29M
Income before tax-$-94.69M-$-85.94M-$-88.69M-$-38.64M-$-18.52M
Income tax expense$180K-$-160K$110K$60K$30K
Net income-$-94.51M-$-85.78M-$-88.8M-$-38.7M-$-18.55M
Weighted average shares outstanding$52.4M$40.4M$29.9M$32.7M$32.7M
Weighted average diluted shares outstanding$52.4M$40.4M$29.9M$32.7M$32.7M
Balance sheet
20252024202320222021
Cash and short-term investments$213.3M$98.7M$91.7M$19.8M$46.3M
Net receivables$990K$780K$7.95M$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$219.1M$104.9M$101M$23.7M$48M
Property, plant and equipment, net$3M$1.69M$1.04M$1.12M$1.29M
Goodwill and intangible assets$13.3M$13.3M$12.2M$12.2M$8.72M
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$17.1M$15.5M$13.3M$13.4M$10.1M
Total assets$236.2M$120.4M$114.4M$37.1M$58M
Accounts payable$1.8M$5.87M$7.6M$3.87M$820K
Short-term debt$500K$320K$170K$140K$190K
Deferred revenue$0.00$0.00$5.95M$0.00$0.00
Total current liabilities$36.8M$44.2M$19.1M$12M$4.06M
Long-term debt$1.81M$860K$430K$122.9M$114.1M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$3.15M$2.73M$1.54M$123M$114.9M
Capital lease obligations$1.81M$1.18M$600K$630K$770K
Total liabilities$39.9M$47M$20.6M$135.1M$119M
Common stock$590K$450K$370K$40K$340K
Retained earnings-$-384.95M-$-285.56M-$-199.78M-$-110.98M-$-72.28M
Accumulated other comprehensive income (loss)$28.3M-$-2.5M-$-1.4M$2.21M$660K
Total equity$196.3M$73.4M$93.7M-$-97.99M-$-60.95M
Total investments$131.8M$71M$53.3M$0.00$0.00
Total debt$2.32M$1.18M$600K$123.1M$114.3M
Net debt-$-79.11M-$-26.53M-$-37.72M$103.3M$68M
Cash flow statement
20252024202320222021
Net income-$-94.51M-$-85.94M-$-88.69M-$-38.64M-$-18.52M
Depreciation and amortization$550K$410K$290K$300K$230K
Stock-based compensation$16M$9.78M$3.61M$800K$330K
Change in working capital-$-70K$14.2M-$-12.99M$6M-$-790K
Accounts receivable$1.9M$250K$40K-$-150K$230K
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-1.86M-$-1.71M$3.73M$3.04M$30K
Net cash provided by operating activities-$-62.22M-$-47.5M-$-53.84M-$-25.07M-$-13.82M
Investments in property, plant and equipment-$-1.33M-$-230K-$-50K-$-70K-$-30K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-59.38M-$-17.56M-$-54.21M-$-3.55M-$-30K
Common stock issued$179M$53.5M$135.6M$0.00$0.00
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$178.6M$54M$129.7M$1.71M$55.2M
Net change in cash$57.2M-$-10.62M$18.5M-$-26.49M$41.3M
Cash at end of period$81.4M$27.7M$38.3M$19.8M$46.3M
Operating cash flow-$-62.22M-$-47.5M-$-53.84M-$-25.07M-$-13.82M
Capital expenditure-$-290K-$-230K-$-50K-$-3.55M-$-30K
Free cash flow-$-62.51M-$-47.73M-$-53.89M-$-28.62M-$-13.85M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Oculis Holding AG

        Oculis Holding AG is a biopharmaceutical company in the clinical development stage, specializing in the creation of innovative eye drop medications for various ocular conditions, addressing both the anterior and posterior segments of the eye. A key asset in its therapeutic portfolio is OCS-01, a topical formulation of dexamethasone, currently progressing through Phase 3 clinical trials for the management of diabetic macular edema. Additionally, OCS-02, a topically administered biological candidate, is engaged in Phase 2b clinical studies to treat keratoconjunctivitis sicca, commonly known as dry eye disease. The company is also advancing OCS-05, an innovative neuroprotective agent, which targets acute optic neuritis and an array of other neuro-ophthalmic disorders, including glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. This enterprise maintains its headquarters in Zug, Switzerland.

        CEO
        Riad Sherif
        Employees
        60
        Beta
        0.23

        Explore

        Frequently asked questions

        What is the intrinsic value of Oculis Holding AG (OCS)?

        InvestorsCraft does not currently publish an intrinsic value for OCS. How the IC value is calculated.

        Is OCS undervalued?

        InvestorsCraft does not publish an undervaluation signal for OCS at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.